The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion
Rev. Assoc. Med. Bras. (1992)
;
64(3): 230-233, Mar. 2018. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-896447
ABSTRACT
Summary Objective: The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE). Method: Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well. Results: The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found. Conclusion: Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Paclitaxel
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de la Angiogénesis
/
Bevacizumab
/
Neoplasias Pulmonares
/
Antineoplásicos Fitogénicos
Tipo de estudio:
Estudio diagnóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Rev. Assoc. Med. Bras. (1992)
Año:
2018
Tipo del documento:
Artículo
País de afiliación:
China
Institución/País de afiliación:
7 Hospital/CN
Similares
MEDLINE
...
LILACS
LIS